Skip to content

Clinical trials

Cardiomyopathy, Dilated trials in Spain

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathy, Dilated Country / region: Spain Clear all

16 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20091
20101
20111
20131
20142
20182
20203
20211
20222
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed5
Terminated4
Active, not recruiting3
Recruiting2
Unknown status2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hospital General Universitario Gregorio Marañon3
Alexion Pharmaceuticals, Inc.1
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud1
Bristol-Myers Squibb1
Centro Medico Teknon1
Cristina Avendaño Solá1
Fundación Pública Andaluza Progreso y Salud1
Hospital Clinic of Barcelona1
Hospital Universitario La Paz1
Institut National de la Santé Et de la Recherche Médicale, France1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathy, Dilated16
Cardiomyopathies4
Cardiomyopathy, Hypertrophic3
Heart Failure3
Stroke2
Atrial Fibrillation1
Campomelic Dysplasia1
Cardiac Output, Low1
Cardiomyopathy, Restrictive1
Coronary Artery Disease1

Trials

Showing 26 to 16 of 16. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.